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Phenylketonuria  (PKU)  is  an  autosomal  recessive  metabolic  disease,  which  is  seen  in  approximately 
1:12,000– 1:18,000 newborn.1,2 PKU results from a deficiency of phenylalanine hydroxylase, the enzyme 
converting phenylalanine into tyrosine. Hyperphenylalaninemia is the biochemical hallmark of PKU. Classic 
phenylketonuria  is  caused  by  a  complete  or  near-complete  deficiency  of  phenylalanine  hydroxylase 
activity;3  without  dietary  restriction  of  phenylalanine,  patients  will  develop  profound  and  irreversible 
intellectual disability and neurological disturbances.2 The natural history of this disorder has been changed 
since newborn screening was introduced in the late 1960s, and affected children are now maintained on a 
phenylalanine restricted diet, which must commence as soon as possible after birth and should continue 
for  life.4,5  Skin  disorders  linked  with  PKU  are  principally  scleroderma-like  changes  with  guttate  or 
generalized  morphea  and  hypopigmentation;  dermatitis  is  also  described  in  these  patients.6–10  An 
accurate  description  of  clinical  features  of  this  dermatitis  cannot  be  found  in  the  literature,  and  the 
relationship with atopic dermatitis, a multifactorial, inflammatory skin disease with a chronic or relapsing 
course, has never been analyzed thoroughly.11–13
Case report
We report the case of a 44-year-old Caucasian man with PKU complicated with atopic dermatitis referred to 
our institution for the worsening of erythematous areas of white scales, crusts, and multiple scratching 
lesions located at forearms, shoulders, inferior limbs, and sacral region (Figs. 1a and 2a). The Fitzpatrick 
phototype was I. Personal history revealed PKU first diagnosed at eight years old; PKU was not recognized 
in the neonatal period, thus the patient had a free diet that resulted in a permanent mental handicap. In 
addition, after PKU diagnosis, adhesion to dietary restriction was poor because of low family compliance. 
Since childhood, the patient has suffered from dermatitis with chronic pruritus and frequent infectious 
episodes,  which  has  been  diagnosed  as  atopic  dermatitis  and  treated for  years  with  topical  steroids. 
Previous patch tests (with the European Standard Series of haptens) were negative. Biochemistry revealed 
leukocytosis (white blood cell count 10.34 9 109/L) with eosinophilia (13%; absolute count: 1.87 9 109/L) 
and elevation of IgE  levels  (4145 kUI/L);  plasma phenylalanine concentration was 1250 lmol/L (normal 
values lower than 120 lmol/L);  flow cytometry on peripheral  blood lymphocytes failed to document an 
imbalance  between  different  T-cell  populations.  Skin  culture  on  lesions  identified  a  non-MRSA 
Staphylococcus  aureus.  Histological  findings  were  nonspecific,  showing  spongiosis,  acanthosis, 
hyperkeratosis,  and increased number of dermal lymphocytes (Fig.  3).  The patient was treated with IV 
steroids  (IV  methylprednisolone  0.5  mg/kg  daily),  azithromycin,  and  topical  tacrolimus.  A  strict,  low 
phenylalanine diet  was started with a  phenylalanine  intake not exceeding 400 mg/day.  IV steroid was 
tapered, and the patient was discharged with topical tacrolimus and dietary treatment only. Owing to good 
compliance with the diet, the plasma phenylalanine concentration dropped to 450 lmol/L in one month; 
tacrolimus was stopped one month later. After six months of dietary treatment, we observed an almost 
complete  cutaneous  response  with  regression  of  erythematous  lesions  and  itching  (Figs.  1b  and  2b), 
together  with  a  reduction  of  IgE  (2712  kUI/L)  and eosinophil  value  (0.7  9  109/L).  This  case  could  be 
considered as a PKU-related eczema but also a true extrinsic atopic dermatitis. Its peculiarity is represented 
by  the  surprising  long-lasting  clinical  response  to  the  dietary  regimen.  The  report  by  Riva  et  al. 
demonstrates that IgE levels are higher in patients with PKU than in the normal population and suggests 
that a dietary regimen can control the development of immunoallergic signs and symptoms.11 
Our report confirms that dietary regimen could not only avoid mental retardation in childhood but also 
reduce the incidence of cutaneous manifestations in PKU. This evidence can also provide an explanation to 
the reduced incidence of eczema in the patient with PKU observed in the last years.
References
1 Smith I, Cook B, Beasley M. Review of neonatal screening programme for phenylketonuria. Br Med J 1991; 
303: 333–335.
2 Walter JH. Late effects of phenylketonuria. Arch Dis Childh 1995; 73: 485–486.
3 Scriver CR, Clow CR. Phenylketonuria: epitome of human biochemical genetics. N Engl J Med 1980; 303: 
1336–1342.
4 Williams RA, Mamotte CD, Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. Clin 
Biochem Rev 2008; 29: 31–41.
5 Longo N, Ernst S. Management of phenylketonuria. US Pediatr 2008; 4: 59–62.
6 Foti R, Leonardi R, Rondinone R, et al. Scleroderma-like disorders. Autoimmunity Rev 2008; 7: 331–339.
7 Guillet G, Dore N, Hehunstre J, et al. Pseudoscleroderma and phenylketonuria. Int J Dermatol 1983; 22: 
422–426.
8 Al-Mayouf SM, Al-Owain MA. Progressive sclerodermatous skin changes in a child with phenylketonuria. 
Pediatr Dermatol 2006; 23: 136–138.
9 Fistarol SK, Itin PH. Disorders of pigmentation. J Dtsch Dermatol Ges 2010; 8: 187–201.
10 Belloso LM, Lowitt MH. Cutaneous findings  in a 51- year-old man with phenylketonuria.  J Am Acad 
Dermatol 2003; 49: S190–S192.
11 Riva E, Fiocchi A, Agostoni C, et al.  PKU-related dysgammaglobulinaemia: the effect of diet therapy on 
IgE and allergic sensitization. J Inherit Metab Dis 1994; 17: 710–717.
12 De Benedetto A, Agnihothri R, McGirt LY, et al. Atopic dermatitis: a disease caused by innate immune 
defects? J Invest Dermatol 2009; 129: 14–30.
13 Fisch RO, Tsai MY, Gentry WC Jr. Studies of phenylketonurics with dermatitis. J Am Acad Dermatol 1981; 
4: 284–290.
Figure 1 Clinical picture of the patient before (a) and 6 months after (b) phenylalanine-restricted diet
Figure 2 Clinical picture of the patient before (a) and 6 months after (b) phenylalanine-restricted diet
Figure  3  Skin  biopsy  shows  spongiosis,  acanthosis,  hyperkeratosis,  and  increased  number  of  dermal 
lymphocytes (hematoxylin and eosin, 9100)
